nodes	percent_of_prediction	percent_of_DWPC	metapath
Almotriptan—migraine—Prednisone—psoriasis	0.479	1	CpDpCtD
Almotriptan—CYP2C8—Tazarotene—psoriasis	0.0436	0.125	CbGbCtD
Almotriptan—CYP1A2—Clobetasol propionate—psoriasis	0.0414	0.118	CbGbCtD
Almotriptan—CYP1A2—Methoxsalen—psoriasis	0.0218	0.0622	CbGbCtD
Almotriptan—CYP2D6—Hydroxyurea—psoriasis	0.0196	0.056	CbGbCtD
Almotriptan—CYP2C8—Cholecalciferol—psoriasis	0.0186	0.0532	CbGbCtD
Almotriptan—CYP2C8—Mycophenolate mofetil—psoriasis	0.0162	0.0461	CbGbCtD
Almotriptan—CYP2C19—Cholecalciferol—psoriasis	0.0156	0.0446	CbGbCtD
Almotriptan—CYP3A4—Calcitriol—psoriasis	0.0147	0.0419	CbGbCtD
Almotriptan—FMO3—sweat—psoriasis	0.0132	0.961	CbGeAlD
Almotriptan—CYP2C8—Hydrocortisone—psoriasis	0.013	0.037	CbGbCtD
Almotriptan—CYP2C8—Cyclosporine—psoriasis	0.0122	0.0349	CbGbCtD
Almotriptan—CYP2D6—Cholecalciferol—psoriasis	0.0119	0.0339	CbGbCtD
Almotriptan—CYP3A4—Methoxsalen—psoriasis	0.0114	0.0326	CbGbCtD
Almotriptan—CYP2C19—Prednisone—psoriasis	0.0108	0.0309	CbGbCtD
Almotriptan—CYP2E1—Dexamethasone—psoriasis	0.0108	0.0308	CbGbCtD
Almotriptan—CYP2C19—Cyclosporine—psoriasis	0.0103	0.0293	CbGbCtD
Almotriptan—CYP2C8—Dexamethasone—psoriasis	0.00806	0.023	CbGbCtD
Almotriptan—CYP2D6—Cyclosporine—psoriasis	0.00781	0.0223	CbGbCtD
Almotriptan—CYP3A4—Cholecalciferol—psoriasis	0.00756	0.0216	CbGbCtD
Almotriptan—CYP2C19—Dexamethasone—psoriasis	0.00676	0.0193	CbGbCtD
Almotriptan—CYP3A4—Mycophenolate mofetil—psoriasis	0.00655	0.0187	CbGbCtD
Almotriptan—CYP3A4—Triamcinolone—psoriasis	0.00655	0.0187	CbGbCtD
Almotriptan—CYP3A4—Betamethasone—psoriasis	0.00562	0.016	CbGbCtD
Almotriptan—CYP3A4—Prednisolone—psoriasis	0.00555	0.0158	CbGbCtD
Almotriptan—CYP3A4—Hydrocortisone—psoriasis	0.00526	0.015	CbGbCtD
Almotriptan—CYP3A4—Prednisone—psoriasis	0.00524	0.015	CbGbCtD
Almotriptan—CYP2D6—Dexamethasone—psoriasis	0.00514	0.0147	CbGbCtD
Almotriptan—CYP3A4—Cyclosporine—psoriasis	0.00496	0.0142	CbGbCtD
Almotriptan—CYP3A4—Dexamethasone—psoriasis	0.00327	0.00933	CbGbCtD
Almotriptan—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00117	0.0528	CbGpPWpGaD
Almotriptan—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00101	0.0457	CbGpPWpGaD
Almotriptan—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000906	0.0408	CbGpPWpGaD
Almotriptan—FMO3—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000835	0.0376	CbGpPWpGaD
Almotriptan—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000833	0.0375	CbGpPWpGaD
Almotriptan—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000777	0.035	CbGpPWpGaD
Almotriptan—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.000727	0.0327	CbGpPWpGaD
Almotriptan—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000629	0.0283	CbGpPWpGaD
Almotriptan—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000561	0.0253	CbGpPWpGaD
Almotriptan—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000516	0.0232	CbGpPWpGaD
Almotriptan—FMO3—Biological oxidations—CYP2S1—psoriasis	0.000444	0.02	CbGpPWpGaD
Almotriptan—FMO3—Metapathway biotransformation—CYP2S1—psoriasis	0.000438	0.0197	CbGpPWpGaD
Almotriptan—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000437	0.0197	CbGpPWpGaD
Almotriptan—MAOA—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000399	0.018	CbGpPWpGaD
Almotriptan—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000338	0.0152	CbGpPWpGaD
Almotriptan—MAOA—tendon—psoriasis	0.00031	0.0226	CbGeAlD
Almotriptan—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000302	0.0136	CbGpPWpGaD
Almotriptan—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000298	0.0134	CbGpPWpGaD
Almotriptan—FMO3—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000276	0.0124	CbGpPWpGaD
Almotriptan—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000261	0.0118	CbGpPWpGaD
Almotriptan—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000258	0.0116	CbGpPWpGaD
Almotriptan—MAOA—Oxidative Stress—CAT—psoriasis	0.000258	0.0116	CbGpPWpGaD
Almotriptan—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000245	0.011	CbGpPWpGaD
Almotriptan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000233	0.0105	CbGpPWpGaD
Almotriptan—CYP2E1—tendon—psoriasis	0.000232	0.017	CbGeAlD
Almotriptan—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00023	0.0104	CbGpPWpGaD
Almotriptan—FMO3—SIDS Susceptibility Pathways—IL13—psoriasis	0.000218	0.00979	CbGpPWpGaD
Almotriptan—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000214	0.00965	CbGpPWpGaD
Almotriptan—MAOA—Biological oxidations—CYP2S1—psoriasis	0.000212	0.00954	CbGpPWpGaD
Almotriptan—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000212	0.00953	CbGpPWpGaD
Almotriptan—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000212	0.00952	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—HCAR2—psoriasis	0.000208	0.00937	CbGpPWpGaD
Almotriptan—MAOA—Melatonin metabolism and effects—APOE—psoriasis	0.000206	0.00925	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—HCAR2—psoriasis	0.000204	0.00917	CbGpPWpGaD
Almotriptan—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000189	0.0085	CbGpPWpGaD
Almotriptan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000182	0.00817	CbGpPWpGaD
Almotriptan—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000179	0.00807	CbGpPWpGaD
Almotriptan—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000174	0.00782	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000166	0.00745	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000162	0.00729	CbGpPWpGaD
Almotriptan—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000147	0.00663	CbGpPWpGaD
Almotriptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00014	0.00631	CbGpPWpGaD
Almotriptan—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000139	0.00625	CbGpPWpGaD
Almotriptan—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000138	0.00623	CbGpPWpGaD
Almotriptan—FMO3—SIDS Susceptibility Pathways—IL10—psoriasis	0.000136	0.00613	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000132	0.00593	CbGpPWpGaD
Almotriptan—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.00013	0.00586	CbGpPWpGaD
Almotriptan—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000128	0.00578	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—HCAR2—psoriasis	0.000126	0.00567	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—HCAR2—psoriasis	0.000123	0.00555	CbGpPWpGaD
Almotriptan—MAOA—Melatonin metabolism and effects—NFKB1—psoriasis	0.000122	0.0055	CbGpPWpGaD
Almotriptan—MAOA—Oxidative Stress—NFKB1—psoriasis	0.000119	0.00536	CbGpPWpGaD
Almotriptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000114	0.00511	CbGpPWpGaD
Almotriptan—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000112	0.00506	CbGpPWpGaD
Almotriptan—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000112	0.00505	CbGpPWpGaD
Almotriptan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000112	0.00505	CbGpPWpGaD
Almotriptan—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000111	0.00499	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—CCL20—psoriasis	0.000108	0.00487	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—CCL20—psoriasis	0.000106	0.00477	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—IL13—psoriasis	0.000104	0.00468	CbGpPWpGaD
Almotriptan—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.0001	0.00452	CbGpPWpGaD
Almotriptan—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	9.9e-05	0.00446	CbGpPWpGaD
Almotriptan—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	9.73e-05	0.00438	CbGpPWpGaD
Almotriptan—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.67e-05	0.00435	CbGpPWpGaD
Almotriptan—CYP2D6—Biological oxidations—CYP2S1—psoriasis	9.23e-05	0.00416	CbGpPWpGaD
Almotriptan—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	9.1e-05	0.0041	CbGpPWpGaD
Almotriptan—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	8.95e-05	0.00403	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—NDUFA5—psoriasis	8.92e-05	0.00402	CbGpPWpGaD
Almotriptan—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	8.9e-05	0.00401	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	8.71e-05	0.00392	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.6e-05	0.00387	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.42e-05	0.00379	CbGpPWpGaD
Almotriptan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.34e-05	0.00375	CbGpPWpGaD
Almotriptan—CYP1A2—Biological oxidations—CYP2S1—psoriasis	7.82e-05	0.00352	CbGpPWpGaD
Almotriptan—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	7.81e-05	0.00058	CcSEcCtD
Almotriptan—Immune system disorder—Prednisone—psoriasis	7.79e-05	0.000579	CcSEcCtD
Almotriptan—Malaise—Dexamethasone—psoriasis	7.78e-05	0.000578	CcSEcCtD
Almotriptan—Malaise—Betamethasone—psoriasis	7.78e-05	0.000578	CcSEcCtD
Almotriptan—Anaphylactic shock—Triamcinolone—psoriasis	7.76e-05	0.000577	CcSEcCtD
Almotriptan—Vertigo—Dexamethasone—psoriasis	7.75e-05	0.000576	CcSEcCtD
Almotriptan—Vertigo—Betamethasone—psoriasis	7.75e-05	0.000576	CcSEcCtD
Almotriptan—Syncope—Dexamethasone—psoriasis	7.73e-05	0.000575	CcSEcCtD
Almotriptan—Syncope—Betamethasone—psoriasis	7.73e-05	0.000575	CcSEcCtD
Almotriptan—Pain—Mycophenolate mofetil—psoriasis	7.73e-05	0.000575	CcSEcCtD
Almotriptan—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	7.71e-05	0.00347	CbGpPWpGaD
Almotriptan—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	7.7e-05	0.00347	CbGpPWpGaD
Almotriptan—Feeling abnormal—Cyclosporine—psoriasis	7.64e-05	0.000568	CcSEcCtD
Almotriptan—Shock—Triamcinolone—psoriasis	7.63e-05	0.000567	CcSEcCtD
Almotriptan—Insomnia—Prednisolone—psoriasis	7.63e-05	0.000567	CcSEcCtD
Almotriptan—FMO3—Metabolism—CYP2S1—psoriasis	7.59e-05	0.00342	CbGpPWpGaD
Almotriptan—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	7.58e-05	0.00341	CbGpPWpGaD
Almotriptan—Gastrointestinal pain—Cyclosporine—psoriasis	7.58e-05	0.000564	CcSEcCtD
Almotriptan—Loss of consciousness—Betamethasone—psoriasis	7.58e-05	0.000564	CcSEcCtD
Almotriptan—Loss of consciousness—Dexamethasone—psoriasis	7.58e-05	0.000564	CcSEcCtD
Almotriptan—Dizziness—Mycophenolic acid—psoriasis	7.58e-05	0.000563	CcSEcCtD
Almotriptan—Epistaxis—Methotrexate—psoriasis	7.58e-05	0.000563	CcSEcCtD
Almotriptan—Paraesthesia—Prednisolone—psoriasis	7.57e-05	0.000563	CcSEcCtD
Almotriptan—Tachycardia—Triamcinolone—psoriasis	7.57e-05	0.000563	CcSEcCtD
Almotriptan—Mental disorder—Prednisone—psoriasis	7.56e-05	0.000562	CcSEcCtD
Almotriptan—Erythema—Prednisone—psoriasis	7.51e-05	0.000558	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.51e-05	0.000558	CcSEcCtD
Almotriptan—Hyperhidrosis—Triamcinolone—psoriasis	7.5e-05	0.000558	CcSEcCtD
Almotriptan—Convulsion—Dexamethasone—psoriasis	7.47e-05	0.000556	CcSEcCtD
Almotriptan—Convulsion—Betamethasone—psoriasis	7.47e-05	0.000556	CcSEcCtD
Almotriptan—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.45e-05	0.000554	CcSEcCtD
Almotriptan—Insomnia—Hydrocortisone—psoriasis	7.45e-05	0.000554	CcSEcCtD
Almotriptan—Hypertension—Dexamethasone—psoriasis	7.45e-05	0.000554	CcSEcCtD
Almotriptan—Hypertension—Betamethasone—psoriasis	7.45e-05	0.000554	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.44e-05	0.00335	CbGpPWpGaD
Almotriptan—Paraesthesia—Hydrocortisone—psoriasis	7.4e-05	0.00055	CcSEcCtD
Almotriptan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.39e-05	0.00055	CcSEcCtD
Almotriptan—Myalgia—Dexamethasone—psoriasis	7.34e-05	0.000546	CcSEcCtD
Almotriptan—Myalgia—Betamethasone—psoriasis	7.34e-05	0.000546	CcSEcCtD
Almotriptan—Abdominal pain—Cyclosporine—psoriasis	7.33e-05	0.000545	CcSEcCtD
Almotriptan—Body temperature increased—Cyclosporine—psoriasis	7.33e-05	0.000545	CcSEcCtD
Almotriptan—Anxiety—Dexamethasone—psoriasis	7.32e-05	0.000544	CcSEcCtD
Almotriptan—Anxiety—Betamethasone—psoriasis	7.32e-05	0.000544	CcSEcCtD
Almotriptan—Vomiting—Mycophenolic acid—psoriasis	7.29e-05	0.000542	CcSEcCtD
Almotriptan—Discomfort—Dexamethasone—psoriasis	7.25e-05	0.000539	CcSEcCtD
Almotriptan—Discomfort—Betamethasone—psoriasis	7.25e-05	0.000539	CcSEcCtD
Almotriptan—Dyspepsia—Hydrocortisone—psoriasis	7.25e-05	0.000539	CcSEcCtD
Almotriptan—Rash—Mycophenolic acid—psoriasis	7.22e-05	0.000537	CcSEcCtD
Almotriptan—Dermatitis—Mycophenolic acid—psoriasis	7.22e-05	0.000537	CcSEcCtD
Almotriptan—Pain—Prednisolone—psoriasis	7.21e-05	0.000536	CcSEcCtD
Almotriptan—Headache—Mycophenolic acid—psoriasis	7.18e-05	0.000534	CcSEcCtD
Almotriptan—Pharyngitis—Methotrexate—psoriasis	7.16e-05	0.000532	CcSEcCtD
Almotriptan—Abdominal pain—Mycophenolate mofetil—psoriasis	7.15e-05	0.000532	CcSEcCtD
Almotriptan—Body temperature increased—Mycophenolate mofetil—psoriasis	7.15e-05	0.000532	CcSEcCtD
Almotriptan—HTR1D—GPCR downstream signaling—HCAR2—psoriasis	7.12e-05	0.00321	CbGpPWpGaD
Almotriptan—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.11e-05	0.000529	CcSEcCtD
Almotriptan—Fatigue—Hydrocortisone—psoriasis	7.1e-05	0.000528	CcSEcCtD
Almotriptan—Vision blurred—Prednisone—psoriasis	7.08e-05	0.000526	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.07e-05	0.000526	CcSEcCtD
Almotriptan—Pain—Hydrocortisone—psoriasis	7.04e-05	0.000524	CcSEcCtD
Almotriptan—Anaphylactic shock—Dexamethasone—psoriasis	7.04e-05	0.000523	CcSEcCtD
Almotriptan—Anaphylactic shock—Betamethasone—psoriasis	7.04e-05	0.000523	CcSEcCtD
Almotriptan—Insomnia—Triamcinolone—psoriasis	7.02e-05	0.000522	CcSEcCtD
Almotriptan—HTR1B—GPCR downstream signaling—HCAR2—psoriasis	6.97e-05	0.00314	CbGpPWpGaD
Almotriptan—Ill-defined disorder—Prednisone—psoriasis	6.97e-05	0.000518	CcSEcCtD
Almotriptan—Paraesthesia—Triamcinolone—psoriasis	6.97e-05	0.000518	CcSEcCtD
Almotriptan—Feeling abnormal—Prednisolone—psoriasis	6.95e-05	0.000517	CcSEcCtD
Almotriptan—Visual impairment—Methotrexate—psoriasis	6.95e-05	0.000517	CcSEcCtD
Almotriptan—Shock—Betamethasone—psoriasis	6.92e-05	0.000515	CcSEcCtD
Almotriptan—Shock—Dexamethasone—psoriasis	6.92e-05	0.000515	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—JUN—psoriasis	6.92e-05	0.00311	CbGpPWpGaD
Almotriptan—Dyspnoea—Triamcinolone—psoriasis	6.92e-05	0.000514	CcSEcCtD
Almotriptan—Nervous system disorder—Betamethasone—psoriasis	6.9e-05	0.000513	CcSEcCtD
Almotriptan—Nervous system disorder—Dexamethasone—psoriasis	6.9e-05	0.000513	CcSEcCtD
Almotriptan—Agitation—Prednisone—psoriasis	6.9e-05	0.000513	CcSEcCtD
Almotriptan—Tachycardia—Betamethasone—psoriasis	6.87e-05	0.000511	CcSEcCtD
Almotriptan—Tachycardia—Dexamethasone—psoriasis	6.87e-05	0.000511	CcSEcCtD
Almotriptan—Angioedema—Prednisone—psoriasis	6.86e-05	0.00051	CcSEcCtD
Almotriptan—Hypersensitivity—Cyclosporine—psoriasis	6.83e-05	0.000508	CcSEcCtD
Almotriptan—Dyspepsia—Triamcinolone—psoriasis	6.83e-05	0.000508	CcSEcCtD
Almotriptan—Nausea—Mycophenolic acid—psoriasis	6.81e-05	0.000506	CcSEcCtD
Almotriptan—Hyperhidrosis—Betamethasone—psoriasis	6.8e-05	0.000506	CcSEcCtD
Almotriptan—Hyperhidrosis—Dexamethasone—psoriasis	6.8e-05	0.000506	CcSEcCtD
Almotriptan—Feeling abnormal—Hydrocortisone—psoriasis	6.79e-05	0.000505	CcSEcCtD
Almotriptan—Malaise—Prednisone—psoriasis	6.77e-05	0.000504	CcSEcCtD
Almotriptan—Vertigo—Prednisone—psoriasis	6.75e-05	0.000502	CcSEcCtD
Almotriptan—CYP1A2—Tryptophan metabolism—CAT—psoriasis	6.75e-05	0.00304	CbGpPWpGaD
Almotriptan—Eye disorder—Methotrexate—psoriasis	6.74e-05	0.000501	CcSEcCtD
Almotriptan—Gastrointestinal pain—Hydrocortisone—psoriasis	6.74e-05	0.000501	CcSEcCtD
Almotriptan—Syncope—Prednisone—psoriasis	6.73e-05	0.000501	CcSEcCtD
Almotriptan—Tinnitus—Methotrexate—psoriasis	6.72e-05	0.0005	CcSEcCtD
Almotriptan—Cardiac disorder—Methotrexate—psoriasis	6.69e-05	0.000498	CcSEcCtD
Almotriptan—Fatigue—Triamcinolone—psoriasis	6.69e-05	0.000497	CcSEcCtD
Almotriptan—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.66e-05	0.000495	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.66e-05	0.003	CbGpPWpGaD
Almotriptan—Asthenia—Cyclosporine—psoriasis	6.65e-05	0.000495	CcSEcCtD
Almotriptan—Pain—Triamcinolone—psoriasis	6.63e-05	0.000493	CcSEcCtD
Almotriptan—Loss of consciousness—Prednisone—psoriasis	6.6e-05	0.000491	CcSEcCtD
Almotriptan—Pruritus—Cyclosporine—psoriasis	6.56e-05	0.000488	CcSEcCtD
Almotriptan—HTR1D—GPCR ligand binding—CCL20—psoriasis	6.55e-05	0.00295	CbGpPWpGaD
Almotriptan—Immune system disorder—Methotrexate—psoriasis	6.51e-05	0.000484	CcSEcCtD
Almotriptan—Abdominal pain—Hydrocortisone—psoriasis	6.51e-05	0.000484	CcSEcCtD
Almotriptan—Body temperature increased—Hydrocortisone—psoriasis	6.51e-05	0.000484	CcSEcCtD
Almotriptan—Convulsion—Prednisone—psoriasis	6.51e-05	0.000484	CcSEcCtD
Almotriptan—MAOA—SIDS Susceptibility Pathways—IL10—psoriasis	6.5e-05	0.00293	CbGpPWpGaD
Almotriptan—Asthenia—Mycophenolate mofetil—psoriasis	6.49e-05	0.000482	CcSEcCtD
Almotriptan—Hypertension—Prednisone—psoriasis	6.48e-05	0.000482	CcSEcCtD
Almotriptan—Chills—Methotrexate—psoriasis	6.47e-05	0.000481	CcSEcCtD
Almotriptan—HTR1D—Signaling by GPCR—HCAR2—psoriasis	6.47e-05	0.00291	CbGpPWpGaD
Almotriptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.44e-05	0.0029	CbGpPWpGaD
Almotriptan—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.41e-05	0.000477	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Betamethasone—psoriasis	6.41e-05	0.000477	CcSEcCtD
Almotriptan—HTR1B—GPCR ligand binding—CCL20—psoriasis	6.41e-05	0.00289	CbGpPWpGaD
Almotriptan—Pruritus—Mycophenolate mofetil—psoriasis	6.4e-05	0.000476	CcSEcCtD
Almotriptan—Arthralgia—Prednisone—psoriasis	6.39e-05	0.000475	CcSEcCtD
Almotriptan—Myalgia—Prednisone—psoriasis	6.39e-05	0.000475	CcSEcCtD
Almotriptan—Feeling abnormal—Triamcinolone—psoriasis	6.39e-05	0.000475	CcSEcCtD
Almotriptan—Anxiety—Prednisone—psoriasis	6.37e-05	0.000474	CcSEcCtD
Almotriptan—Insomnia—Betamethasone—psoriasis	6.37e-05	0.000473	CcSEcCtD
Almotriptan—Insomnia—Dexamethasone—psoriasis	6.37e-05	0.000473	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.35e-05	0.000472	CcSEcCtD
Almotriptan—Diarrhoea—Cyclosporine—psoriasis	6.34e-05	0.000472	CcSEcCtD
Almotriptan—HTR1B—Signaling by GPCR—HCAR2—psoriasis	6.33e-05	0.00285	CbGpPWpGaD
Almotriptan—Paraesthesia—Betamethasone—psoriasis	6.32e-05	0.00047	CcSEcCtD
Almotriptan—Paraesthesia—Dexamethasone—psoriasis	6.32e-05	0.00047	CcSEcCtD
Almotriptan—Discomfort—Prednisone—psoriasis	6.32e-05	0.00047	CcSEcCtD
Almotriptan—Mental disorder—Methotrexate—psoriasis	6.32e-05	0.00047	CcSEcCtD
Almotriptan—Erythema—Methotrexate—psoriasis	6.28e-05	0.000467	CcSEcCtD
Almotriptan—Hypersensitivity—Prednisolone—psoriasis	6.21e-05	0.000462	CcSEcCtD
Almotriptan—Dyspepsia—Dexamethasone—psoriasis	6.2e-05	0.000461	CcSEcCtD
Almotriptan—Dyspepsia—Betamethasone—psoriasis	6.2e-05	0.000461	CcSEcCtD
Almotriptan—Diarrhoea—Mycophenolate mofetil—psoriasis	6.19e-05	0.00046	CcSEcCtD
Almotriptan—Dysgeusia—Methotrexate—psoriasis	6.15e-05	0.000457	CcSEcCtD
Almotriptan—Body temperature increased—Triamcinolone—psoriasis	6.13e-05	0.000456	CcSEcCtD
Almotriptan—Dizziness—Cyclosporine—psoriasis	6.13e-05	0.000456	CcSEcCtD
Almotriptan—Anaphylactic shock—Prednisone—psoriasis	6.13e-05	0.000456	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Betamethasone—psoriasis	6.08e-05	0.000452	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Dexamethasone—psoriasis	6.08e-05	0.000452	CcSEcCtD
Almotriptan—Back pain—Methotrexate—psoriasis	6.07e-05	0.000451	CcSEcCtD
Almotriptan—Hypersensitivity—Hydrocortisone—psoriasis	6.07e-05	0.000451	CcSEcCtD
Almotriptan—Fatigue—Dexamethasone—psoriasis	6.07e-05	0.000451	CcSEcCtD
Almotriptan—Fatigue—Betamethasone—psoriasis	6.07e-05	0.000451	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.04e-05	0.00272	CbGpPWpGaD
Almotriptan—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.04e-05	0.00272	CbGpPWpGaD
Almotriptan—Shock—Prednisone—psoriasis	6.03e-05	0.000448	CcSEcCtD
Almotriptan—Pain—Betamethasone—psoriasis	6.02e-05	0.000448	CcSEcCtD
Almotriptan—Pain—Dexamethasone—psoriasis	6.02e-05	0.000448	CcSEcCtD
Almotriptan—Nervous system disorder—Prednisone—psoriasis	6.01e-05	0.000447	CcSEcCtD
Almotriptan—Tachycardia—Prednisone—psoriasis	5.98e-05	0.000445	CcSEcCtD
Almotriptan—Dizziness—Mycophenolate mofetil—psoriasis	5.98e-05	0.000445	CcSEcCtD
Almotriptan—Skin disorder—Prednisone—psoriasis	5.95e-05	0.000443	CcSEcCtD
Almotriptan—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.95e-05	0.00268	CbGpPWpGaD
Almotriptan—Hyperhidrosis—Prednisone—psoriasis	5.93e-05	0.000441	CcSEcCtD
Almotriptan—Vision blurred—Methotrexate—psoriasis	5.92e-05	0.00044	CcSEcCtD
Almotriptan—Asthenia—Hydrocortisone—psoriasis	5.91e-05	0.00044	CcSEcCtD
Almotriptan—Vomiting—Cyclosporine—psoriasis	5.89e-05	0.000438	CcSEcCtD
Almotriptan—Rash—Cyclosporine—psoriasis	5.84e-05	0.000435	CcSEcCtD
Almotriptan—Dermatitis—Cyclosporine—psoriasis	5.84e-05	0.000434	CcSEcCtD
Almotriptan—Pruritus—Hydrocortisone—psoriasis	5.83e-05	0.000433	CcSEcCtD
Almotriptan—Ill-defined disorder—Methotrexate—psoriasis	5.82e-05	0.000433	CcSEcCtD
Almotriptan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.82e-05	0.00262	CbGpPWpGaD
Almotriptan—Headache—Cyclosporine—psoriasis	5.81e-05	0.000432	CcSEcCtD
Almotriptan—Feeling abnormal—Betamethasone—psoriasis	5.8e-05	0.000431	CcSEcCtD
Almotriptan—Feeling abnormal—Dexamethasone—psoriasis	5.8e-05	0.000431	CcSEcCtD
Almotriptan—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	5.79e-05	0.0026	CbGpPWpGaD
Almotriptan—Gastrointestinal pain—Betamethasone—psoriasis	5.76e-05	0.000428	CcSEcCtD
Almotriptan—Gastrointestinal pain—Dexamethasone—psoriasis	5.76e-05	0.000428	CcSEcCtD
Almotriptan—Vomiting—Mycophenolate mofetil—psoriasis	5.75e-05	0.000428	CcSEcCtD
Almotriptan—Hypersensitivity—Triamcinolone—psoriasis	5.71e-05	0.000425	CcSEcCtD
Almotriptan—Rash—Mycophenolate mofetil—psoriasis	5.7e-05	0.000424	CcSEcCtD
Almotriptan—Dermatitis—Mycophenolate mofetil—psoriasis	5.7e-05	0.000424	CcSEcCtD
Almotriptan—Headache—Mycophenolate mofetil—psoriasis	5.66e-05	0.000421	CcSEcCtD
Almotriptan—Malaise—Methotrexate—psoriasis	5.66e-05	0.000421	CcSEcCtD
Almotriptan—Vertigo—Methotrexate—psoriasis	5.64e-05	0.000419	CcSEcCtD
Almotriptan—Diarrhoea—Hydrocortisone—psoriasis	5.64e-05	0.000419	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Prednisone—psoriasis	5.58e-05	0.000415	CcSEcCtD
Almotriptan—Dizziness—Prednisolone—psoriasis	5.58e-05	0.000415	CcSEcCtD
Almotriptan—Asthenia—Triamcinolone—psoriasis	5.57e-05	0.000414	CcSEcCtD
Almotriptan—Abdominal pain—Betamethasone—psoriasis	5.56e-05	0.000414	CcSEcCtD
Almotriptan—Abdominal pain—Dexamethasone—psoriasis	5.56e-05	0.000414	CcSEcCtD
Almotriptan—Body temperature increased—Betamethasone—psoriasis	5.56e-05	0.000414	CcSEcCtD
Almotriptan—Body temperature increased—Dexamethasone—psoriasis	5.56e-05	0.000414	CcSEcCtD
Almotriptan—Insomnia—Prednisone—psoriasis	5.54e-05	0.000412	CcSEcCtD
Almotriptan—Nausea—Cyclosporine—psoriasis	5.51e-05	0.000409	CcSEcCtD
Almotriptan—Paraesthesia—Prednisone—psoriasis	5.5e-05	0.000409	CcSEcCtD
Almotriptan—Pruritus—Triamcinolone—psoriasis	5.49e-05	0.000408	CcSEcCtD
Almotriptan—Dizziness—Hydrocortisone—psoriasis	5.45e-05	0.000405	CcSEcCtD
Almotriptan—Convulsion—Methotrexate—psoriasis	5.44e-05	0.000404	CcSEcCtD
Almotriptan—Dyspepsia—Prednisone—psoriasis	5.4e-05	0.000401	CcSEcCtD
Almotriptan—Nausea—Mycophenolate mofetil—psoriasis	5.37e-05	0.000399	CcSEcCtD
Almotriptan—Myalgia—Methotrexate—psoriasis	5.34e-05	0.000397	CcSEcCtD
Almotriptan—Chest pain—Methotrexate—psoriasis	5.34e-05	0.000397	CcSEcCtD
Almotriptan—Arthralgia—Methotrexate—psoriasis	5.34e-05	0.000397	CcSEcCtD
Almotriptan—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.32e-05	0.0024	CbGpPWpGaD
Almotriptan—Rash—Prednisolone—psoriasis	5.32e-05	0.000395	CcSEcCtD
Almotriptan—Dermatitis—Prednisolone—psoriasis	5.31e-05	0.000395	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.31e-05	0.000395	CcSEcCtD
Almotriptan—Fatigue—Prednisone—psoriasis	5.28e-05	0.000393	CcSEcCtD
Almotriptan—Headache—Prednisolone—psoriasis	5.28e-05	0.000393	CcSEcCtD
Almotriptan—Discomfort—Methotrexate—psoriasis	5.28e-05	0.000393	CcSEcCtD
Almotriptan—Vomiting—Hydrocortisone—psoriasis	5.24e-05	0.000389	CcSEcCtD
Almotriptan—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.21e-05	0.00234	CbGpPWpGaD
Almotriptan—Rash—Hydrocortisone—psoriasis	5.19e-05	0.000386	CcSEcCtD
Almotriptan—Dermatitis—Hydrocortisone—psoriasis	5.19e-05	0.000386	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—TNF—psoriasis	5.18e-05	0.00233	CbGpPWpGaD
Almotriptan—Confusional state—Methotrexate—psoriasis	5.17e-05	0.000384	CcSEcCtD
Almotriptan—Headache—Hydrocortisone—psoriasis	5.16e-05	0.000384	CcSEcCtD
Almotriptan—Dizziness—Triamcinolone—psoriasis	5.13e-05	0.000381	CcSEcCtD
Almotriptan—Anaphylactic shock—Methotrexate—psoriasis	5.12e-05	0.000381	CcSEcCtD
Almotriptan—Feeling abnormal—Prednisone—psoriasis	5.05e-05	0.000376	CcSEcCtD
Almotriptan—Asthenia—Betamethasone—psoriasis	5.05e-05	0.000375	CcSEcCtD
Almotriptan—Asthenia—Dexamethasone—psoriasis	5.05e-05	0.000375	CcSEcCtD
Almotriptan—Nervous system disorder—Methotrexate—psoriasis	5.02e-05	0.000374	CcSEcCtD
Almotriptan—Gastrointestinal pain—Prednisone—psoriasis	5.01e-05	0.000373	CcSEcCtD
Almotriptan—Nausea—Prednisolone—psoriasis	5.01e-05	0.000373	CcSEcCtD
Almotriptan—Pruritus—Betamethasone—psoriasis	4.98e-05	0.00037	CcSEcCtD
Almotriptan—Pruritus—Dexamethasone—psoriasis	4.98e-05	0.00037	CcSEcCtD
Almotriptan—Skin disorder—Methotrexate—psoriasis	4.98e-05	0.00037	CcSEcCtD
Almotriptan—Hyperhidrosis—Methotrexate—psoriasis	4.95e-05	0.000368	CcSEcCtD
Almotriptan—Vomiting—Triamcinolone—psoriasis	4.93e-05	0.000367	CcSEcCtD
Almotriptan—Nausea—Hydrocortisone—psoriasis	4.89e-05	0.000364	CcSEcCtD
Almotriptan—Rash—Triamcinolone—psoriasis	4.89e-05	0.000364	CcSEcCtD
Almotriptan—Dermatitis—Triamcinolone—psoriasis	4.89e-05	0.000363	CcSEcCtD
Almotriptan—Headache—Triamcinolone—psoriasis	4.86e-05	0.000361	CcSEcCtD
Almotriptan—Abdominal pain—Prednisone—psoriasis	4.85e-05	0.00036	CcSEcCtD
Almotriptan—Body temperature increased—Prednisone—psoriasis	4.85e-05	0.00036	CcSEcCtD
Almotriptan—Diarrhoea—Dexamethasone—psoriasis	4.82e-05	0.000358	CcSEcCtD
Almotriptan—Diarrhoea—Betamethasone—psoriasis	4.82e-05	0.000358	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Methotrexate—psoriasis	4.67e-05	0.000347	CcSEcCtD
Almotriptan—Dizziness—Betamethasone—psoriasis	4.65e-05	0.000346	CcSEcCtD
Almotriptan—Dizziness—Dexamethasone—psoriasis	4.65e-05	0.000346	CcSEcCtD
Almotriptan—Insomnia—Methotrexate—psoriasis	4.63e-05	0.000345	CcSEcCtD
Almotriptan—Nausea—Triamcinolone—psoriasis	4.61e-05	0.000343	CcSEcCtD
Almotriptan—Paraesthesia—Methotrexate—psoriasis	4.6e-05	0.000342	CcSEcCtD
Almotriptan—Dyspnoea—Methotrexate—psoriasis	4.57e-05	0.00034	CcSEcCtD
Almotriptan—Somnolence—Methotrexate—psoriasis	4.55e-05	0.000339	CcSEcCtD
Almotriptan—Hypersensitivity—Prednisone—psoriasis	4.52e-05	0.000336	CcSEcCtD
Almotriptan—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.51e-05	0.00203	CbGpPWpGaD
Almotriptan—Dyspepsia—Methotrexate—psoriasis	4.51e-05	0.000335	CcSEcCtD
Almotriptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.49e-05	0.00202	CbGpPWpGaD
Almotriptan—Vomiting—Betamethasone—psoriasis	4.47e-05	0.000333	CcSEcCtD
Almotriptan—Vomiting—Dexamethasone—psoriasis	4.47e-05	0.000333	CcSEcCtD
Almotriptan—Rash—Betamethasone—psoriasis	4.44e-05	0.00033	CcSEcCtD
Almotriptan—Rash—Dexamethasone—psoriasis	4.44e-05	0.00033	CcSEcCtD
Almotriptan—Dermatitis—Betamethasone—psoriasis	4.43e-05	0.00033	CcSEcCtD
Almotriptan—Dermatitis—Dexamethasone—psoriasis	4.43e-05	0.00033	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Methotrexate—psoriasis	4.42e-05	0.000329	CcSEcCtD
Almotriptan—Fatigue—Methotrexate—psoriasis	4.42e-05	0.000328	CcSEcCtD
Almotriptan—Headache—Dexamethasone—psoriasis	4.41e-05	0.000328	CcSEcCtD
Almotriptan—Headache—Betamethasone—psoriasis	4.41e-05	0.000328	CcSEcCtD
Almotriptan—Asthenia—Prednisone—psoriasis	4.4e-05	0.000327	CcSEcCtD
Almotriptan—Pain—Methotrexate—psoriasis	4.38e-05	0.000326	CcSEcCtD
Almotriptan—Pruritus—Prednisone—psoriasis	4.34e-05	0.000322	CcSEcCtD
Almotriptan—MAOA—Metabolism—NDUFA5—psoriasis	4.26e-05	0.00192	CbGpPWpGaD
Almotriptan—Feeling abnormal—Methotrexate—psoriasis	4.22e-05	0.000314	CcSEcCtD
Almotriptan—Diarrhoea—Prednisone—psoriasis	4.19e-05	0.000312	CcSEcCtD
Almotriptan—Gastrointestinal pain—Methotrexate—psoriasis	4.19e-05	0.000311	CcSEcCtD
Almotriptan—Nausea—Betamethasone—psoriasis	4.18e-05	0.000311	CcSEcCtD
Almotriptan—Nausea—Dexamethasone—psoriasis	4.18e-05	0.000311	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—IL6—psoriasis	4.18e-05	0.00188	CbGpPWpGaD
Almotriptan—Dizziness—Prednisone—psoriasis	4.05e-05	0.000301	CcSEcCtD
Almotriptan—Body temperature increased—Methotrexate—psoriasis	4.05e-05	0.000301	CcSEcCtD
Almotriptan—Abdominal pain—Methotrexate—psoriasis	4.05e-05	0.000301	CcSEcCtD
Almotriptan—Vomiting—Prednisone—psoriasis	3.9e-05	0.00029	CcSEcCtD
Almotriptan—Rash—Prednisone—psoriasis	3.86e-05	0.000287	CcSEcCtD
Almotriptan—Dermatitis—Prednisone—psoriasis	3.86e-05	0.000287	CcSEcCtD
Almotriptan—Headache—Prednisone—psoriasis	3.84e-05	0.000286	CcSEcCtD
Almotriptan—HTR1D—Signaling Pathways—HCAR2—psoriasis	3.82e-05	0.00172	CbGpPWpGaD
Almotriptan—Hypersensitivity—Methotrexate—psoriasis	3.77e-05	0.000281	CcSEcCtD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.75e-05	0.00169	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—HCAR2—psoriasis	3.74e-05	0.00168	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—CARM1—psoriasis	3.71e-05	0.00167	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—CCL20—psoriasis	3.7e-05	0.00167	CbGpPWpGaD
Almotriptan—Asthenia—Methotrexate—psoriasis	3.68e-05	0.000273	CcSEcCtD
Almotriptan—Nausea—Prednisone—psoriasis	3.64e-05	0.000271	CcSEcCtD
Almotriptan—MAOA—Metabolism—CYP2S1—psoriasis	3.63e-05	0.00163	CbGpPWpGaD
Almotriptan—Pruritus—Methotrexate—psoriasis	3.62e-05	0.000269	CcSEcCtD
Almotriptan—HTR1B—GPCR downstream signaling—CCL20—psoriasis	3.62e-05	0.00163	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—CXCL8—psoriasis	3.56e-05	0.0016	CbGpPWpGaD
Almotriptan—Diarrhoea—Methotrexate—psoriasis	3.5e-05	0.000261	CcSEcCtD
Almotriptan—Dizziness—Methotrexate—psoriasis	3.39e-05	0.000252	CcSEcCtD
Almotriptan—HTR1D—Signaling by GPCR—CCL20—psoriasis	3.36e-05	0.00151	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TAGAP—psoriasis	3.31e-05	0.00149	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—JUN—psoriasis	3.31e-05	0.00149	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—CCL20—psoriasis	3.29e-05	0.00148	CbGpPWpGaD
Almotriptan—Vomiting—Methotrexate—psoriasis	3.26e-05	0.000242	CcSEcCtD
Almotriptan—HTR1B—Signaling Pathways—TAGAP—psoriasis	3.24e-05	0.00146	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.24e-05	0.00146	CbGpPWpGaD
Almotriptan—Rash—Methotrexate—psoriasis	3.23e-05	0.00024	CcSEcCtD
Almotriptan—Dermatitis—Methotrexate—psoriasis	3.23e-05	0.00024	CcSEcCtD
Almotriptan—Headache—Methotrexate—psoriasis	3.21e-05	0.000239	CcSEcCtD
Almotriptan—MAOA—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.18e-05	0.00143	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.12e-05	0.0014	CbGpPWpGaD
Almotriptan—Nausea—Methotrexate—psoriasis	3.04e-05	0.000226	CcSEcCtD
Almotriptan—HTR1D—G alpha (i) signalling events—CXCL8—psoriasis	2.92e-05	0.00131	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.89e-05	0.0013	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—CXCL8—psoriasis	2.86e-05	0.00129	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.83e-05	0.00127	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—NDUFA5—psoriasis	2.62e-05	0.00118	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—TNF—psoriasis	2.48e-05	0.00111	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.42e-05	0.00109	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.42e-05	0.00109	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.32e-05	0.00104	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—CAT—psoriasis	2.28e-05	0.00103	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.27e-05	0.00102	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—NDUFA5—psoriasis	2.26e-05	0.00102	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CYP2S1—psoriasis	2.22e-05	0.001	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.11e-05	0.000949	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—NDUFA5—psoriasis	2.02e-05	0.000909	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—IL6—psoriasis	2e-05	0.000899	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—CCL20—psoriasis	1.98e-05	0.000893	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—CCL20—psoriasis	1.94e-05	0.000875	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CYP2S1—psoriasis	1.92e-05	0.000866	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.88e-05	0.000847	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—NDUFA5—psoriasis	1.86e-05	0.000836	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—CARM1—psoriasis	1.77e-05	0.000797	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—APOE—psoriasis	1.77e-05	0.000797	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—CXCL8—psoriasis	1.77e-05	0.000796	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—CXCL8—psoriasis	1.73e-05	0.000779	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CYP2S1—psoriasis	1.72e-05	0.000773	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CYP2S1—psoriasis	1.58e-05	0.000711	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—NDUFA5—psoriasis	1.57e-05	0.000708	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—PPARG—psoriasis	1.54e-05	0.000694	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.47e-05	0.00066	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CYP2S1—psoriasis	1.34e-05	0.000602	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—NDUFA5—psoriasis	1.21e-05	0.000546	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—SOCS1—psoriasis	1.09e-05	0.000492	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—CAT—psoriasis	1.09e-05	0.00049	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CARM1—psoriasis	1.09e-05	0.000489	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—SOCS1—psoriasis	1.07e-05	0.000482	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—TYK2—psoriasis	1.04e-05	0.000469	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CYP2S1—psoriasis	1.03e-05	0.000465	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—TYK2—psoriasis	1.02e-05	0.000459	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.01e-05	0.000454	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—CXCL8—psoriasis	9.99e-06	0.00045	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—CXCL8—psoriasis	9.78e-06	0.00044	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CARM1—psoriasis	9.39e-06	0.000423	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—CXCL8—psoriasis	9.07e-06	0.000408	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.99e-06	0.000405	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—CXCL8—psoriasis	8.88e-06	0.0004	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.78e-06	0.000395	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—APOE—psoriasis	8.46e-06	0.000381	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CARM1—psoriasis	8.38e-06	0.000377	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—APOE—psoriasis	8.06e-06	0.000363	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—LEP—psoriasis	8.06e-06	0.000363	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—LEP—psoriasis	7.9e-06	0.000355	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—APOE—psoriasis	7.9e-06	0.000355	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.83e-06	0.000353	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CARM1—psoriasis	7.71e-06	0.000347	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—NFKBIA—psoriasis	7.52e-06	0.000338	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—PPARG—psoriasis	7.37e-06	0.000332	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—NFKBIA—psoriasis	7.36e-06	0.000331	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.01e-06	0.000315	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CAT—psoriasis	6.68e-06	0.000301	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CARM1—psoriasis	6.53e-06	0.000294	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TYK2—psoriasis	6.16e-06	0.000277	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.1e-06	0.000275	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TYK2—psoriasis	6.03e-06	0.000271	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CAT—psoriasis	5.78e-06	0.00026	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—CXCL8—psoriasis	5.36e-06	0.000241	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—CXCL8—psoriasis	5.25e-06	0.000236	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—APOE—psoriasis	5.19e-06	0.000234	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CAT—psoriasis	5.16e-06	0.000232	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—IL6—psoriasis	5.1e-06	0.000229	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CARM1—psoriasis	5.04e-06	0.000227	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—IL6—psoriasis	4.99e-06	0.000225	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—JUN—psoriasis	4.98e-06	0.000224	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—JUN—psoriasis	4.88e-06	0.00022	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—NFKB1—psoriasis	4.8e-06	0.000216	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CAT—psoriasis	4.74e-06	0.000213	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—NFKB1—psoriasis	4.7e-06	0.000211	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—PPARG—psoriasis	4.52e-06	0.000204	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—APOE—psoriasis	4.49e-06	0.000202	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—VEGFA—psoriasis	4.35e-06	0.000196	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—STAT3—psoriasis	4.31e-06	0.000194	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—VEGFA—psoriasis	4.26e-06	0.000192	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—STAT3—psoriasis	4.22e-06	0.00019	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CAT—psoriasis	4.02e-06	0.000181	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—APOE—psoriasis	4.01e-06	0.00018	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—PPARG—psoriasis	3.91e-06	0.000176	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—APOE—psoriasis	3.68e-06	0.000166	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—PPARG—psoriasis	3.49e-06	0.000157	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TP53—psoriasis	3.29e-06	0.000148	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TP53—psoriasis	3.22e-06	0.000145	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—PPARG—psoriasis	3.21e-06	0.000144	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—APOE—psoriasis	3.12e-06	0.00014	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CAT—psoriasis	3.1e-06	0.00014	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—IL6—psoriasis	3.01e-06	0.000136	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—IL6—psoriasis	2.95e-06	0.000133	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—PPARG—psoriasis	2.72e-06	0.000122	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—APOE—psoriasis	2.41e-06	0.000108	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—PPARG—psoriasis	2.1e-06	9.44e-05	CbGpPWpGaD
